key: cord-0896766-i0u7qywz
authors: Papadakos, Stavros P; Mazonakis, Nikolaos; Papadakis, Michail; Tsioutis, Constantinos; Spernovasilis, Nikolaos
title: Pill versus Vaccine for COVID-19: Is there a genuine dilemma?
date: 2021-11-23
journal: Ethics Med Public Health
DOI: 10.1016/j.jemep.2021.100741
sha: 9c9db2c58b93c0ee51e4248b92d2abf121feb047
doc_id: 896766
cord_uid: i0u7qywz

nan

On March 11 2020 the World Health Organization (WHO) upgraded officially the awareness level over COVID-19 from a Public Health Emergency of International Concern (PHEIC) to a pandemic. A coordinated attempt of the scientific community accelerated the SARS-CoV-2 genome and structural analysis, shedding light into the virological properties, biology of the disease and pathophysiology of infection, and set the grounds for the vaccine development process. Vaccines are an efficient approach to achieve widespread immunity, reducing disease morbidity and mortality and raising the selective pressure plateau, limiting the formation of novel viral variants, thus constituting the cornerstone of disease-preventive strategies.

Currently, the viral-vector and the nucleic-acid vaccines for COVID J o u r n a l P r e -p r o o f 3 application is based on encouraging results from a phase 3 clinical trial of unvaccinated, nonhospitalized adult patients with mild-to-moderate disease at increased risk for severe , which demonstrated that a 5-day course of Molnupiravir, 800mg twice daily within 5 days of symptom onset, reduced approximately 50% the risk of hospitalization or death. This agent is also being evaluated for post-exposure prophylaxis in the context of prevention of COVID-19 spread [3] . Molnupiravir is a prodrug that can be metabolized into a ribonucleoside analog, whose active ribonucleotide form can be incorporated into viral RNA, forcing it to lethal mutagenesis during replication [4] . However, there are theoretical concerns about its potential risk for genotoxicity, as its deoxyribonucleotide metabolite is mutagenic to host cell DNA [5] .

However, available data until now indicate that the drug is not genotoxic in in vivo mammalian systems. PF-07321332 (Pfizer) is another oral antiviral, which is currently evaluated in phase 3 clinical trials. It is a 3-chymotrypsin-like protease inhibitor (3CLpro) that interferes with the formation of viable viral particles [6] . It is administered in combination with ritonavir (Paxlovid, PF-07321332; ritonavir) within 5 days of symptom onset in non-hospitalized participants with symptomatic COVID-19 at increased risk of progressing to severe illness.

The results of the interim analysis of the Phase 2/3 EPIC-HR study showed a reduction in the risk of hopitalization or death by 89% in high-risk outpatients [7] . A study for the assessment of Paxlovid as post-exposure prophylaxis is also ongoing. [8] . It is also of determining importance that they can be easily modified in order to target mutated variants, with limited financial disbursement in a relatively short time. Finally, further analyses have demonstrated that the wide use of vaccines is a cost-effective preventive measure, especially when compared to other prevention strategies [9] . One of the highlighted drawbacks is the need for continuous evaluation of their effectiveness and duration of protection that they provide [8] . It's worth noting that serious side effects have been reported In conclusion, in our perspective the "vaccine vs pill" debate turns out to be a false dilemma, as it is evident that both pharmaceutical options, vaccines and oral antivirals, have unique, distinct and complementary roles in the management of the COVID-19 pandemic. 

COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks

Announce initiation of a rolling review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells

Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection

Pfizer's Novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study

Early approval of COVID-19 vaccines: Pros and cons

The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of costeffectiveness modeling to inform vaccination prioritization

COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection